Want to see BVNRY full AI Analyst Report?
BVNRY Stock Chart & Stats
$11.07
$0.05(0.61%)
At close: 4:00 PM EDT
$11.07
$0.05(0.61%)
Day’s Range― - ―
52-Week Range$8.81 - $12.54
Previous CloseN/A
Volume411.00
Average Volume (3M)235.00
Market Cap
$2.65B
Enterprise Value$1.78K
Total Cash (Recent Filing)$2.36B
Total Debt (Recent Filing)$131.35M
Price to Earnings (P/E)10.9
Beta0.69
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield7.68%
Share Statistics
EPS (TTM)6.64
Shares Outstanding237,712,550
10 Day Avg. Volume565
30 Day Avg. Volume235
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.15
Price to Sales (P/S)2.49
P/FCF Ratio6.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal leverage gives Bavarian Nordic substantial financial resilience and flexibility to fund manufacturing, pipeline development, acquisitions, or shareholder returns without heavy debt-service pressure.
Strong Profitability And Cash GenerationThe combination of high operating profitability and substantial positive free cash flow supports self-funded growth and demonstrates that the current vaccine portfolio can generate meaningful earnings and liquidity.
Broadening Commercial GrowthGrowth across travel vaccines and secured preparedness contracts broadens the revenue base beyond a single product, while rising rabies and TBE demand supports commercial scale over the next several quarters.
Bears Say
Government Demand VariabilityReliance on government tenders, stockpiling, and outbreak responses makes revenue timing inherently uneven, creating a persistent risk that future procurement cycles will not match current preparedness strength.
Margin Sustainability UncertaintyRecent margins benefited from campaign manufacturing efficiencies and favorable product mix, so normalization could reduce earnings power if those temporary operational benefits do not persist across future production cycles.
Product Execution And Regulatory HeadwindsDelayed U.S. guidance can slow chikungunya adoption, while shorter TBE shelf life may create returns and channel friction; together these issues could constrain near-term portfolio growth and execution.
Bavarian Nordic News
BVNRY FAQ
What was Bavarian Nordic A/S’s price range in the past 12 months?
Bavarian Nordic A/S lowest stock price was $8.80 and its highest was $12.54 in the past 12 months.
What is Bavarian Nordic A/S’s market cap?
Bavarian Nordic A/S’s market cap is $2.65B.
When is Bavarian Nordic A/S’s upcoming earnings report date?
Bavarian Nordic A/S’s upcoming earnings report date is Nov 13, 2026 which is in 67 days.
How were Bavarian Nordic A/S’s earnings last quarter?
Bavarian Nordic A/S released its earnings results on Aug 21, 2026. The company reported $0.5 earnings per share for the quarter.
Is Bavarian Nordic A/S overvalued?
According to Wall Street analysts Bavarian Nordic A/S’s price is currently Overvalued.
Does Bavarian Nordic A/S pay dividends?
Bavarian Nordic A/S pays a Notavailable dividend of $0.426 which represents an annual dividend yield of 7.68%. See more information on Bavarian Nordic A/S dividends here
What is Bavarian Nordic A/S’s EPS estimate?
Bavarian Nordic A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bavarian Nordic A/S have?
Bavarian Nordic A/S has 237,712,550 shares outstanding.
What happened to Bavarian Nordic A/S’s price movement after its last earnings report?
Bavarian Nordic A/S reported an EPS of $0.5 in its last earnings report. Following the earnings report the stock price went up 8.968%.
Which hedge fund is a major shareholder of Bavarian Nordic A/S?
Currently, no hedge funds are holding shares in BVNRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bavarian Nordic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Bavarian Nordic A/S
Bavarian Nordic A/S is a Danish biopharmaceutical company specializing in the development, production, and global commercialization of essential, life-saving vaccines. Its marketed portfolio includes non-replicating vaccines for smallpox and monkeypox (known as IMVAMUNE, IMVANEX, and JYNNEOS), as well as human rabies protection (Rabipur/RabAvert), a tick-borne encephalitis vaccine (Encepur), and an Ebola vaccine (MVABEA). The company also boasts a robust pipeline of investigational therapies. Notably, MVA-BN (freeze-dried) has concluded Phase III trials for smallpox, and MVA-BN RSV is currently in Phase III clinical development for respiratory syncytial virus (RSV). Additionally, ABNCoV2, a candidate for SARS-CoV-2, successfully completed its Phase II clinical trial, and TAEK-VAC is advancing through Phase I/II studies for select advanced HER2 and brachyury-expressing cancers. Bavarian Nordic maintains strategic alliances, including a licensing and collaboration agreement with AdaptVac, alongside further licensing arrangements with the National Cancer Institute and the Public Health Service. Its commercial operations and presence span numerous countries, such as the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, and Japan, reflecting a broad international footprint. Established in 1992, Bavarian Nordic A/S is headquartered in Hellerup, Denmark.
BVNRY Company Deck
BVNRY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive picture: strong H1 revenue (DKK 3.092 billion), high gross (61%) and EBITDA margins (35% H1; 45% Q2), upgraded full-year revenue and margin guidance (DKK 5.7 billion and ~30%), a robust cash position (DKK 2.3 billion) and an expanded share buyback program (up to DKK 750 million). Growth across Travel Health (26% H1, 45% Q2), particularly rabies (+40% H1) and TBE (+17% H1), plus meaningful pipeline progress (EBV Phase I, promising Lyme preclinical data) reinforce a constructive outlook. Key near-term negatives include a downgrade to Vimkunya sales guidance (to DKK 200 million) due to delayed U.S. ACIP guidance, temporary shelf-life constraints on TBE with return risk, and an H1 cash flow impact from a one‑off milestone payment. Overall, the positive operational and financial momentum outweigh the identifiable short-term headwinds.View all BVNRY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
― Other Institutional Investors
99.98% Public Companies and
Individual Investors